TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11784276

Group type: EXPERIMENTAL
Intervention: Nondistally fixated (open kinetic chain) leg extensor resistance training
Number of subjects: 43

Group type: COMPARATOR
Intervention: Distally fixated (closed kinetic chain) leg extensor resistance training
Number of subjects: 43
Study: 9829845

Group type: EXPERIMENTAL
Intervention: Normal samples and middle fractions of samples with anisocytosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extreme fractions of elutriation profile
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fractions with largest red cells of microcytic series and smallest red cells of normo- and macrocytic samples
Number of subjects: 0
Study: 7655254

Group type: EXPERIMENTAL
Intervention: Patient managed learning and nurse directed teaching strategy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional face‐to‐face methods
Number of subjects: 34
Study: 2514458

Group type: EXPERIMENTAL
Intervention: Aseptic alginate impression material (Blueprint asept)
Number of subjects: 0
Study: 4582563

Group type: EXPERIMENTAL
Intervention: Amantadine alone
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Amantadine combined with levodopa
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo instead of amantadine
Number of subjects: 77
Study: 31829767

Group type: EXPERIMENTAL
Intervention: AS04-HPV-16/18 vaccine
Number of subjects: 32175

Group type: COMPARATOR
Intervention: Hepatitis-B virus vaccine (control)
Number of subjects: 32175
Study: 30664075

Group type: EXPERIMENTAL
Intervention: Immediate antiretroviral therapy (ART)
Number of subjects: 0
Study: 29185589

Group type: EXPERIMENTAL
Intervention: Bevacizumab-gefitinib-WBRT
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Gefitinib-WBRT
Number of subjects: 218

Group type: COMPARATOR
Intervention: WBRT
Number of subjects: 218
Study: 25765099

Group type: EXPERIMENTAL
Intervention: rhGH + 150 rhIGF-1 (45/150 µg/kg)
Number of subjects: 180

Group type: COMPARATOR
Intervention: rhGH alone (group A)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: rhGH + 50 rhIGF-1 (group B)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: rhGH + 100 rhIGF-1 (group C)
Number of subjects: 180
Study: 23460356

Group type: EXPERIMENTAL
Intervention: Primary wound closure
Number of subjects: 120

Group type: COMPARATOR
Intervention: Delayed wound closure
Number of subjects: 120
Study: 21219089

Group type: EXPERIMENTAL
Intervention: Ecologically-oriented, strategy-based intervention for memory impairment
Number of subjects: 33
Study: 16798651

Group type: EXPERIMENTAL
Intervention: Oral deferiprone (L1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous desferrioxamine (DFO)
Number of subjects: 0
Study: 12782545

Group type: EXPERIMENTAL
Intervention: 200 mg/day oral androstenedione
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 11243632

Group type: EXPERIMENTAL
Intervention: Skin-identical lipids in a petrolatum-rich cream base
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pure petrolatum
Number of subjects: 0
Study: 9292679

Group type: EXPERIMENTAL
Intervention: Trabecular aspiration technique with negative suction pressure ranging from 100 to 200 mm Hg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no trabecular aspiration)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Trabecular aspiration technique
Number of subjects: 100
Study: 8306157

Group type: EXPERIMENTAL
Intervention: 3% tetracaine hydrochloride
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: 1% lignocaine hydrochloride
Number of subjects: 261

Group type: COMPARATOR
Intervention: No local anaesthetic
Number of subjects: 261
Study: 3792426

Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg every 6 h)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg every 12 h)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31567714

Group type: EXPERIMENTAL
Intervention: 2000 mg of 5% TXA in 100 mL of isotonic saline solution
Number of subjects: 157

Group type: COMPARATOR
Intervention: 100 mL isotonic saline (control group)
Number of subjects: 157
Study: 30287600

Group type: EXPERIMENTAL
Intervention: Magnesium (100 mg/day; n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (n=50)
Number of subjects: 100
Study: 27513739

Group type: EXPERIMENTAL
Intervention: Computer Assisted Femur First (CAS FF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional THR (CON)
Number of subjects: 60
Study: 25297610

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU as retinol, single oral dose)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Iron supplementation (1-2 mg/kg/d, daily for 5 days a week for 6 months)
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Combined vitamin A and iron supplementation
Number of subjects: 445

Group type: COMPARATOR
Intervention: Placebo (no vitamin A or iron)
Number of subjects: 445
Study: 21273285

Group type: EXPERIMENTAL
Intervention: Distalizing force applied to the maxillary canine (test tooth) using a 0.017 × 0.025 inch titanium‐molybdenum alloy archwire
Number of subjects: 16

Group type: COMPARATOR
Intervention: Orthodontic appliance with no force applied to the contralateral canine (control tooth)
Number of subjects: 16
Study: 20433527

Group type: EXPERIMENTAL
Intervention: Lactotripeptides dosed twice daily
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Lactotripeptides in treatment-naive patients
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo in treatment-naive patients
Number of subjects: 91
Study: 19226067

Group type: EXPERIMENTAL
Intervention: Metal-on-metal hip resurfacing
Number of subjects: 21

Group type: COMPARATOR
Intervention: Ceramic-on-ceramic THA
Number of subjects: 21
Study: 16202859

Group type: EXPERIMENTAL
Intervention: Candesartan 2 mg orally
Number of subjects: 26
Study: 12390641

Group type: EXPERIMENTAL
Intervention: Children's ibuprofen suspension (7.5 mg/kg, p.o.)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 10357500

Group type: EXPERIMENTAL
Intervention: Computer-generated physician mammography reminders placed prominently in medical records
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study: 7790641

Group type: EXPERIMENTAL
Intervention: Monetary reinforcement plus instruction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Monetary reinforcement only
Number of subjects: 40

Group type: COMPARATOR
Intervention: Instruction only
Number of subjects: 40

Group type: COMPARATOR
Intervention: Repeat administration
Number of subjects: 40
Study: 2088232

Group type: EXPERIMENTAL
Intervention: Doxycycline (Doximycin) for 2 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 797088

Group type: EXPERIMENTAL
Intervention: Vistarin injections
Number of subjects: 250

Group type: COMPARATOR
Intervention: Varicocide injections
Number of subjects: 250
Study: 30414219

Group type: EXPERIMENTAL
Intervention: Recapture Life (six-session group-based online cognitive-behavioural intervention)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Online peer-support group (control)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 61
Study: 28430175

Group type: EXPERIMENTAL
Intervention: Carfilzomib-lenalidomide-dexamethasone (KRd)
Number of subjects: 0

Group type: COMPARATOR
Intervention: lenalidomide-dexamethasone (Rd)
Number of subjects: 0
Study: 26327554

Group type: EXPERIMENTAL
Intervention: Rotary wing daylight (RW-D)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rotary wing in total darkness using binocular NVG (RW-NVG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Emergency room (ER) setting
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All scenarios
Number of subjects: 12
Study: 24099141

Group type: EXPERIMENTAL
Intervention: EEG biofeedback
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham biofeedback
Number of subjects: 24
Study: 21756768

Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: TACE plus RFA
Number of subjects: 50
Study: 18283261

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 66
Study: 16533414

Group type: EXPERIMENTAL
Intervention: Pulsed-dose oxygen-conserving device (PDOCD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Continuous-flow oxygen
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pulsed-dose oxygen-conserving device (PDOCD) with sensitive triggering sensitivity
Number of subjects: 10
Study: 12648029

Group type: EXPERIMENTAL
Intervention: Ritalin LA 20 mg capsule
Number of subjects: 20

Group type: COMPARATOR
Intervention: Concerta 18 mg tablet
Number of subjects: 20
Study: 11197318

Group type: EXPERIMENTAL
Intervention: Active nicotine patch (21 mg for 6 weeks, then 14 mg for weeks 7-8, and 7 mg for weeks 9-10)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 421
Study: 8956919

Group type: EXPERIMENTAL
Intervention: Topiramate 400 mg/day
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 1573068

Group type: EXPERIMENTAL
Intervention: One-day neonatal resuscitation education program
Number of subjects: 190
Study: 3904817

Group type: EXPERIMENTAL
Intervention: Automatic feedback controlled oxytocin infusion system (AIS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard labour ward protocols (control)
Number of subjects: 0
Study: 31192719

Group type: EXPERIMENTAL
Intervention: Peer support intervention with three sessions of education on Kangaroo Mother Care (KMC)
Number of subjects: 24
Study: 29424243

Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Investigator's choice of chemotherapy
Number of subjects: 0
Study: 26636929

Group type: EXPERIMENTAL
Intervention: CVC 100 mg
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: CVC 200 mg
Number of subjects: 143

Group type: COMPARATOR
Intervention: EFV 600 mg
Number of subjects: 143
Study: 25237065

Group type: EXPERIMENTAL
Intervention: Urinary [TIMP‐2]•[IGFBP7] values of 0.3 or greater
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Urinary [TIMP‐2]•[IGFBP7] values of >2
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Cutoff of ≤0.3 versus >0.3‐2
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Cutoff of ≤0.3 versus >2
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Cutoff of 2.0
Number of subjects: 154
Study: 21870050

Group type: EXPERIMENTAL
Intervention: Laparoscopic duodenojejunal bypass with sleeve (DJB)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Laparoscopic Roux en Y gastric bypass
Number of subjects: 57
Study: 20201841

Group type: EXPERIMENTAL
Intervention: Physiotherapist-guided pelvic floor muscle exercises (PG-PFME)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Instruction folder only (F-PFME)
Number of subjects: 82
Study: 16868362

Group type: EXPERIMENTAL
Intervention: Red fluorescent light (700 lux)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Green fluorescent light (700 lux)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Blue fluorescent light (700 lux)
Number of subjects: 12
Study: 12752518

Group type: EXPERIMENTAL
Intervention: 2,400 U of botulinum toxin type B (Myobloc)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 3,000 U of botulinum toxin type B (Myobloc)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Saline injections (control group)
Number of subjects: 39
Study: 10789172

Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Arthrocentesis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lysis and lavage in the upper compartment of the TMJ
Number of subjects: 0
Study: 9305418

Group type: EXPERIMENTAL
Intervention: Nicotine (0.8 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haloperidol (5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotine (0.8 mg) + Haloperidol (5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo + Haloperidol (5 mg)
Number of subjects: 0
Study: 7818614

Group type: EXPERIMENTAL
Intervention: Dosing rules for phenytoin (PHT)
Number of subjects: 122
Study: 3003315

Group type: EXPERIMENTAL
Intervention: Seronegative blood products
Number of subjects: 35

Group type: COMPARATOR
Intervention: Blood products from random donors
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Acquired CMV infection
Number of subjects: 35
Study: 31398987

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol/ascorbic acid (PEGA) in split-dose regimen
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Oral sulfate formula (SIR) in split-dose regimen
Number of subjects: 558

Group type: COMPARATOR
Intervention: Sodium picosulfate/magnesium citrate (SPMC)
Number of subjects: 558
Study: 30307370

Group type: EXPERIMENTAL
Intervention: Modified constraint‐induced movement therapy and bimanual therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Middle cerebral artery infarct group
Number of subjects: 22
Study: 26358288

Group type: EXPERIMENTAL
Intervention: Semaglutide 1.6 mg E
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Open-label Liraglutide (1.2 or 1.8 mg)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study: 24341659

Group type: EXPERIMENTAL
Intervention: Levamisole (100 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 21515055

Group type: EXPERIMENTAL
Intervention: Patellar reshaping
Number of subjects: 133

Group type: COMPARATOR
Intervention: Patellar resurfacing
Number of subjects: 133
Study: 20572210

Group type: EXPERIMENTAL
Intervention: Pro-ED websites
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthy/exercise websites
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tourist websites
Number of subjects: 100
Study: 17646235

Group type: EXPERIMENTAL
Intervention: Pulmonary radioaerosol mucociliary clearance (PRMC) test
Number of subjects: 95
Study: 17032285

Group type: EXPERIMENTAL
Intervention: 15 mg lansoprazole
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 10 mg rabeprazole
Number of subjects: 20

Group type: COMPARATOR
Intervention: No medication
Number of subjects: 20
Study: 12702905

Group type: EXPERIMENTAL
Intervention: Individualized treatment (group A) - prolonged IFN therapy to maintain negative serum HBV-DNA levels for 6 months
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard treatment (group B) - treated for only 6 months
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Individualized treatment (group A)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard treatment (group B)
Number of subjects: 65
Study: 10714565

Group type: EXPERIMENTAL
Intervention: Zidovudine and didanosine
Number of subjects: 55

Group type: COMPARATOR
Intervention: Zidovudine/didanosine/nevirapine
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Mutant combination 601 + 215Y/F
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Amino acid identity at position 215
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Combinations 215 + 44 and 41 + 202
Number of subjects: 55
Study: 9370846

Group type: EXPERIMENTAL
Intervention: Midazolam 0.03 mg.kg-1
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 48
Study: 8286254

Group type: EXPERIMENTAL
Intervention: Phototesting device with metal foil apertures (1, 2, 4, 8 J/cm2)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Phototesting device
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control device with four open apertures
Number of subjects: 11
Study: 3514473

Group type: EXPERIMENTAL
Intervention: Ofloxacin (OFX) 2 X 200 mg/day (n = 21)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Doxycycline (D) 2 X 100 mg/day (n = 20)
Number of subjects: 41
Study: 30200935

Group type: EXPERIMENTAL
Intervention: Text messaging intervention (delivered 2-3 times weekly with educational, motivational, and supportive content)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (monitoring only)
Number of subjects: 0
Study: 26994063

Group type: EXPERIMENTAL
Intervention: Causal analyses of observational data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Framework for comparative effectiveness research using big data
Number of subjects: 0
Study: 24984178

Group type: EXPERIMENTAL
Intervention: CYP4F2 GA/AA genotype
Number of subjects: 53

Group type: COMPARATOR
Intervention: CYP4F2 GG (wildtype)
Number of subjects: 53
Study: 22642962

Group type: EXPERIMENTAL
Intervention: Low demanding/high responsive feeding style
Number of subjects: 383

Group type: COMPARATOR
Intervention: High demanding/high responsive feeding style
Number of subjects: 383
Study: 20227347

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 19257

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 19257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19257

Group type: COMPARATOR
Intervention: Diuretic
Number of subjects: 19257
Study: 18432382

Group type: EXPERIMENTAL
Intervention: Family drinking and perceived drinking norms
Number of subjects: 1318

Group type: EXPERIMENTAL
Intervention: Perceived benefits of drinking
Number of subjects: 1318
Study: 15757960

Group type: EXPERIMENTAL
Intervention: Screening by abdominal ultrasonography
Number of subjects: 12639

Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 12639
Study: 12860868

Group type: EXPERIMENTAL
Intervention: Low dose lexipafant (10 mg)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: High dose lexipafant (100 mg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 10100181

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) 0.625 mg/day for 21 days + chlormadinone acetate for 5 days
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) 1.25 mg/day for 21 days + chlormadinone acetate for 5 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group of regularly menstruating women
Number of subjects: 50
Study: 8926014

Group type: EXPERIMENTAL
Intervention: Epinephrine (0.10 micrograms/kg/min)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Norepinephrine (0.15 micrograms/kg/min)
Number of subjects: 19

Group type: COMPARATOR
Intervention: NaCl (control)
Number of subjects: 19
Study: 1905495

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (800 IU/day) for 48 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (800 IU/day)
Number of subjects: 21
Study: 6410292

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 139

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study: 31530174

Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) during NH
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure (PEP) during HH
Number of subjects: 13

Group type: COMPARATOR
Intervention: No PEP during HH
Number of subjects: 13

Group type: COMPARATOR
Intervention: No PEP during NN
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: PEP in all sessions
Number of subjects: 13
Study: 29166720

Group type: EXPERIMENTAL
Intervention: Firehawk stent
Number of subjects: 460

Group type: COMPARATOR
Intervention: Xience V stent
Number of subjects: 460
Study: 26024851

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 2910

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2910

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2910
Study: 23059701

Group type: EXPERIMENTAL
Intervention: Behavioural therapy plus usual care
Number of subjects: 105

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 105
Study: 22036946

Group type: EXPERIMENTAL
Intervention: In-person (IP) intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internet-based (IB) intervention
Number of subjects: 0
Study: 17895912

Group type: EXPERIMENTAL
Intervention: Moderate vitamins (vitamin C (300 mg) and E (75 IU) and folic acid (1 mg))
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High doses of vitamins (vitamin C (2 g) and E (800 IU), and folic acid (5 mg))
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cream (high-fat challenge)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15996669

Group type: EXPERIMENTAL
Intervention: Lullaby music during kangaroo care for 60 min/section/day for three consecutive days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine incubator care
Number of subjects: 30
Study: 15200636

Group type: EXPERIMENTAL
Intervention: Computer game that pairs self-relevant information with smiling faces
Number of subjects: 0
Study: 11136518

Group type: EXPERIMENTAL
Intervention: 5 mg/kg/day of pentavalent antimony (Sb5+) for 30 to 45 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 5 mg/kg/day of pentavalent antimony (Sb5+)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Subsequent use of larger doses of antimony
Number of subjects: 36
Study: 9324146

Group type: EXPERIMENTAL
Intervention: Transhiatal (TH) resection
Number of subjects: 39

Group type: COMPARATOR
Intervention: Transthoracic (TT) resection
Number of subjects: 39
Study: 8406345

Group type: EXPERIMENTAL
Intervention: 15 IU of growth hormone/m2/week
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 30 IU of growth hormone/m2/week
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 25
Study: 2936772

Group type: EXPERIMENTAL
Intervention: Erythromycin (1 gm/day for 4 weeks, then 333 mg/day for 8 weeks)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Tetracycline (1 gm/day for 4 weeks, then 500 mg/day for 8 weeks)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 200

Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 200
Study: 29126661

Group type: EXPERIMENTAL
Intervention: Same-day coupon at checkout for half-off eligible fresh, frozen, or canned fruits and vegetables over 4 months
Number of subjects: 401
Study: 28963304

Group type: EXPERIMENTAL
Intervention: Point-of-care (POC) HIV VL monitoring and potential task shifting to enrolled nurses
Number of subjects: 396

Group type: COMPARATOR
Intervention: Laboratory VL monitoring and standard South African HIV care
Number of subjects: 396
Study: 25761367

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (HS)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 35